The association between serum levels of potential biomarkers with the presence of factors related to the clinical activity and poor prognosis in spondyloarthritis

Revista Brasileira de Reumatologia

Volumn 52, Issue 4, 2012, Pages 536-544

  Londono, John ^a,b   Romero Sanchez, Maria Consuelo ^b,c   Torres, Viviana Garcia ^b   Bautista, Wilson A ^d   Fernandez, Diego Jaimes ^b   Quiroga, Julitte de Avila ^e   Valle Oñate, Rafael ^b   Santos, Ana María ^f   Medina, Juan Francisco ^a,g  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSIDAD DE LA SABANA   (Colombia)

^c Univerisdad del Bosque   (Colombia)

^d UNIVERSIDAD MILITAR NUEVA GRANADA   (Colombia)

^e UNIVERSIDAD EL BOSQUE   (Colombia)

^f UNIVERSIDAD DE LOS ANDES   (Colombia)

^g UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Ankylosing spondylitis; Ankylosing spondyloarthritis; Arthritis; Biomarkers; Enthesopathy; Low back pain; Reactive arthritis; Rheumatic diseases; Spondyloarthritis; Spondyloarthropathies

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; HLA B27 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 23; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; SERUM AMYLOID A; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BACKACHE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTHESITIS; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATORY BACK PAIN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PROGNOSIS; PROTEIN BLOOD LEVEL; REACTIVE ARTHRITIS; SACROILIITIS; SPONDYLARTHRITIS; UVEITIS;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; PROGNOSIS; SPONDYLARTHRITIS;

EID: 84866499931     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042012000400006     Document Type: Article

References (49)

1. Khan MA. Espondilite anquilosante: introductory comments on its diagnosis and treatment. Ann Rheum Dis 2002; 61 Suppl 3: iii3-iii7.
2. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 Suppl 3: iii8-18.
3. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr., Dijkmans B et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65 (4): 442-52.
4. Zeidler H, Mau W, Khan MA. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am 1992; 18 (1): 187-202.
5. Khan MA, Kushner I, Braun WE. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 1977; 20 (4): 909-12.
6. Burgos-Vargas R, Vázquez-Mellado J, Cassis N, Duarte C, Casarín J, Cifuentes M et al. Genuine ankylosing spondylitis in children: a case-control study of patients with early definite disease according to adult onset criteria. J Rheumatol 1996; 23 (12): 2140-7.
7. Londoño J, González L, Ramírez A, Santos P, Avila L, Santos A et al. Caracterización de las espondiloartropatías y determinación de factores de mal pronostico en una población de pacientes colombianos. Rev Colomb Reumatol 2005; 12 (3): 195-207.
8. Burgos-Vargas R, Vázquez-Mellado J. The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38 (6): 835-44.
9. Burgos-Vargas R, Pacheco-Tena C, Vázquez-Mellado J. Juvenileonset spondyloarthropathies. Rheum Dis Clin North Am 1997; 23 (3): 569-98.
10. Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21 (10): 1883-7.
11. Khan MA, Kellner H. Immunogenetics of spondyloarthropathies. Rheum Dis Clin North Am 1992; 18 (4): 837-64.
12. Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol 2008; 20 (4): 392-7.
13. Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheumatol 2010; 22 (2): 126-32.
14. Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, Pointon JJ et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010; 42 (2): 123-7.
15. Maksymowych WP. Biomarkers in spondyloarthritis. Curr Rheumatol Rep 2010; 12 (5): 318-24.
16. Maksymowych WP. What do biomarkers tell us about the pathogenesis of ankylosing spondylitis? Arthritis Res Ther 2009; 11(1):101.
17. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26 (4): 980-4.
18. Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006; 45 (4): 414-20.
19. Romero-Sánchez C, Robinson WH, Tomooka BH, Londoño J, Valle-Oñate R, Huang F et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 2008; 27 (11): 1429-35.
20. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26 (2): 211-5.
21. Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004; 51 (5): 691-9.
22. Heumann D, Bas S, Gallay P, Le Roy D, Barras C, Mensi N et al. Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein. J Rheumatol 1995; 22 (7): 1224-9.
23. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 2011; 30 (2): 269-73.
24. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34 (10): 1218-27.
25. Kingsley G, Sieper J. Third International Workshop on Reactive Arthriti. 23-26 September 1995, Berlin, Germany. Report and abstracts. Ann Rheum Dis 1996; 55 (8): 564-84.
26. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21 (12): 2286-91.
27. Calin A, Jones SD, Garrett SL, Kennedy LG. Bath Ankylosing Spondylitis Functional Index. Br J Rheumatol 1995; 34 (8): 793-4.
28. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999; 26 (4): 951-4.
29. de Vlam K. Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2010; 24 (5): 671-82.
30. Chen HA, Chen CH, Liao HT, Lin YJ, Chen PC, Chen WS et al. Factors associated with radiographic spinal involvement and hip involvement in ankylosing spondylitis. Semin Arthritis Rheum 2011; 40 (6): 552-8.
31. Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 2010; 69 (7): 1338-41.
32. Romero-Sánchez C, Londoño J, De Ávila J, Valle-Oñate R. Biomarkers for spondyloarthropathies. State of the art. Rev Med Chil 2010; 138 (9): 1179-85.
33. Pedersen SJ, Hetland ML, Sørensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol 2010; 29 (11): 1301-9.
34. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67 (4): 511-7.
35. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007; 74 (3): 304-5.
36. Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007; 34(11):2285-90.
37. Wendling D, Cedoz JP, Racadot E. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol 2009; 28 (2): 187-90.
38. Weiss J. Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. Biochem Soc Trans 2003; 31(Pt 4):785-90.
39. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265 (2): 501-23.
40. Lange U, Boss B, Teichmann J, Klör HU, Neeck G. Serum amyloid A - an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 2000; 19 (4): 119-22.
41. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009; 61 (11): 1484-90.
42. Zhu J, Yu DT. Matrix metalloproteinase expression in the spondyloarthropathies. Curr Opin Rheumatol 2006; 18 (4): 364-8.
43. Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56 (6): 1846-53.
44. Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S et al. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008; 35 (10): 2030-7.
45. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007; 34 (8): 1753-9.
46. Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008; 10(5):R125.
47. Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004; 50 (9): 2942-53.
48. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011; 70(6):973-81.
49. Pedersen SJ, Sørensen IJ, Lambert RG, Hermann KG, Garnero P, Johansen JS et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor αinhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 2011; 63 (12): 3789-800.